Tenofovir disoproxil fumarate and bone mineral density: A 60-month longitudinal study in a cohort of HIV-infected youths

Antiviral Therapy

Volumn 15, Issue 7, 2010, Pages 1053-1058

  Viganò, Alessandra ^a   Zuccotti, Gian V ^a   Puzzovio, Maria ^b   Pivetti, Valentina ^a   Zamproni, Ilaria ^b   Cerini, Chiara ^a   Fabiano, Valentina ^a   Giacomet, Vania ^a   Mora, Stefano ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; EFAVIRENZ; LAMIVUDINE; PROTEINASE INHIBITOR; STAVUDINE; TENOFOVIR DISOPROXIL;

ADOLESCENT; ARTICLE; BODY SURFACE; BONE DENSITY; BONE METABOLISM; CHILD; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; LUMBAR SPINE; MALE; OSTEOLYSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SCORING SYSTEM; SKELETON; TREATMENT DURATION;

ADENINE; ADOLESCENT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL MARKERS; BONE DENSITY; CHILD; CHILD, PRESCHOOL; COLLAGEN TYPE I; FEMALE; FOLLOW-UP STUDIES; HIV; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; MALE; PEPTIDES; PHOSPHONIC ACIDS; YOUNG ADULT;

EID: 78651094152     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1650     Document Type: Article

References (19)

1. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372:293-299.
2. Obel N, Thomsen HF, Kronborg G, et al. Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. Clin Infect Dis 2007; 44:1625-1631.
3. Kotler DP. HIV and antiretroviral therapy: lipid abnormalities and associated cardiovascular risk in HIV-infected patients. J Acquir Immune Defic Syndr 2008; 49 Suppl 2:S79-S85.
4. Mallewa JE, Wilkins E, Vilar J, et al. HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options. J Antimicrob Chemother 2008; 62:648-660.
5. Viganò A, Mora S. Adverse effects of antiretroviral therapy: focus on bone density. Expert Opin Drug Saf 2004; 3:199-208.
6. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191-201.
7. Jones S, Restrepo D, Kasowitz A, et al. Risk factors for decreased bone density and effects of HIV on bone in the elderly. Osteoporos Int 2008; 19:913-918.
8. Gafni RI, Hazra R, Reynolds JC, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Pediatrics 2006; 118:e711-e718.
9. Purdy JB, Gafni RI, Reynolds JC, Zeichner S, Hazra R. Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. J Pediatr 2008; 152:582-584. (Pubitemid 351381047)
10. Giacomet V, Mora S, Martelli L, Merlo M, Sciannamblo M, Viganò A. A 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected children. J Acquir Immune Defic Syndr 2005; 40:448-450.
11. Giacomet V, Bedogni G, Manfredini V, et al. Renal safety of HAART including tenofovir in vertically HIV-infected youths: a 60-month longitudinal study. 17th Conference on Retroviruses and Opportunistic Infections. 16-19 February 2010, San Francisco, CA, USA. Abstract 870.
12. Cacciari E, Milani S, Balsamo A, et al. A Italian cross-sectional growth charts for height, weight and BMI (2 to 20 yr). J Endocrinol Invest 2006; 29:581-593.
13. Tanner JM, Whitehouse RH. Clinical longitudinal standards for height, weight, height velocity and weight velocity and stages of puberty. Arch Dis Child 1976; 51:170-179.
14. Mora S, Prinster C, Proverbio MC, et al. Urinary markers of bone turnover in healthy children and adolescents: Age-related changes and effect of puberty. Calcif Tissue Int 1998; 63:369-374.
15. Mora S, Cafarelli L, Erba P, et al. Differential effect of age, gender and puberty on bone formation rate assessed by measurement of bone-specific alkaline phosphatase in healthy children and adolescents. J Bone Miner Metab 2009; 27:721-726.
16. Zuccotti G, Viganò A, Gabiano C, et al. Antiretroviral therapy and bone mineral measurements in HIV-infected youths. Bone 2010; 46:1633-1638.
17. Mora S, Sala N, Bricalli D, Zuin G, Chiumello G, Viganò A. Bone mineral loss through increased bone turnover in HIV-infected children treated with highly active antiretroviral therapy. AIDS 2001; 15:1823-1829.
18. Mora S, Zamproni I, Beccio S, Bianchi R, Giacomet V, Viganò A. Longitudinal changes of bone mineral density and metabolism in antiretroviral-treated human immunodeficiency virus-infected children. J Clin Endocrinol Metab 2004; 89:24-28. (Pubitemid 38183854)
19. Mora S, Zamproni I, Cafarelli L, et al. Alterations in circulating osteoimmune factors may be responsible for high bone resorption rate in HIV-infected children and adolescents. AIDS 2007; 21:1129-1135.